Geron Corporation (GERN) - Total Liabilities
Based on the latest financial reports, Geron Corporation (GERN) has total liabilities worth $305.01 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset growth rate of Geron Corporation to track the company's year-over-year net asset growth rate.
Geron Corporation - Total Liabilities Trend (1996–2025)
This chart illustrates how Geron Corporation's total liabilities have evolved over time, based on quarterly financial data. See Geron Corporation free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
Geron Corporation Competitors by Total Liabilities
The table below lists competitors of Geron Corporation ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Abacus Life Inc.
NASDAQ:ABL
|
USA | $479.34 Million |
|
Anhui Huaren Health Pharmaceutical Co. Ltd. Cl A
SHE:301408
|
China | CN¥3.31 Billion |
|
Xencor Inc
NASDAQ:XNCR
|
USA | $243.50 Million |
|
S.J.S. Enterprises Limited
NSE:SJS
|
India | Rs2.31 Billion |
|
engcon AB Cl B
ST:ENGCON-B
|
Sweden | Skr653.00 Million |
|
Xinke Material
SHG:600255
|
China | CN¥2.59 Billion |
|
Ripley Corp
SN:RIPLEY
|
Chile | CL$3.02 Trillion |
|
Standard Motor Products Inc
NYSE:SMP
|
USA | $1.34 Billion |
Liability Composition Analysis (1996–2025)
This chart breaks down Geron Corporation's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see GERN company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.78 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.33 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.57 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Geron Corporation's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Geron Corporation (1996–2025)
The table below shows the annual total liabilities of Geron Corporation from 1996 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $344.67 Million | +9.96% |
| 2024-12-31 | $313.46 Million | +114.51% |
| 2023-12-31 | $146.13 Million | +32.15% |
| 2022-12-31 | $110.58 Million | +11.00% |
| 2021-12-31 | $99.62 Million | +66.64% |
| 2020-12-31 | $59.78 Million | +96.89% |
| 2019-12-31 | $30.36 Million | +302.09% |
| 2018-12-31 | $7.55 Million | +15.88% |
| 2017-12-31 | $6.52 Million | -17.19% |
| 2016-12-31 | $7.87 Million | +18.62% |
| 2015-12-31 | $6.63 Million | -84.13% |
| 2014-12-31 | $41.80 Million | +450.93% |
| 2013-12-31 | $7.59 Million | -46.37% |
| 2012-12-31 | $14.15 Million | +5.24% |
| 2011-12-31 | $13.44 Million | -67.09% |
| 2010-12-31 | $40.85 Million | +423.37% |
| 2009-12-31 | $7.80 Million | +0.54% |
| 2008-12-31 | $7.76 Million | -41.29% |
| 2007-12-31 | $13.22 Million | -71.80% |
| 2006-12-31 | $46.88 Million | +344.88% |
| 2005-12-31 | $10.54 Million | +7.42% |
| 2004-12-31 | $9.81 Million | -16.80% |
| 2003-12-31 | $11.79 Million | -61.88% |
| 2002-12-31 | $30.93 Million | -10.84% |
| 2001-12-31 | $34.69 Million | -30.78% |
| 2000-12-31 | $50.11 Million | +33.63% |
| 1999-12-31 | $37.50 Million | +220.51% |
| 1998-12-31 | $11.70 Million | +134.00% |
| 1997-12-31 | $5.00 Million | -3.85% |
| 1996-12-31 | $5.20 Million | -- |
About Geron Corporation
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lowe… Read more